WC
CYTK icon

Wexford Capital’s Cytokinetics CYTK Stock Holding History

Wexford Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,449
Closed -$79.6K – 416
2025
Q3 		$79.6K Sell
1,449
-3,658
-72% -$151K 0.01% 252
2025
Q2 		$169K Buy
+5,107
New +$178K 0.05% 179

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wexford Capital's CYTK Position: Q4 2025 in Review

Wexford Capital sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 1,449 shares — an estimated $79.6K sold.

Wexford Capital first reported a position in CYTK in Q2 2025 and held it in 2 quarters. The position peaked at $169K in Q2 2025. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

  • Wexford Capital reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
  • Wexford Capital sold 1,449 Cytokinetics shares in Q4 2025, an estimated $79.6K.
  • Wexford Capital first reported a position in Cytokinetics in Q2 2025 and held it in 2 quarters.
  • Wexford Capital's Cytokinetics position peaked at $169K in Q2 2025.
  • 430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Wexford Capital's 13F filing for Q4 2025, filed 13 Feb 2026.